• /  77
  • 下載費用: 19.90積分  

優秀學術報告PPT示例(Ari-Koskinen).ppt

'優秀學術報告PPT示例(Ari-Koskinen).ppt'
Chemistry in Biomedicineand Drug Discovery Professor Ari KoskinenHelsinki University of Technology11.03.2005 Ari KoskinenLaboratory of Organic ChemistryNumberapprovedbyFDA,024,021,718,616,215,513,712,51189,48,27,66,55,84,$/No.New Chemical Entities vs. R&D Expedinture $ billions600,705040302010 086 87 88 89 90 91 92 93 94 95 96 97 98 990,600,500,400,300,200,100,00R&D Spending $billionsNew molecularentities approved byFDARatio: $ / No.Note: Ethical pharmaceuticals only. Expenditures worldwide by U.S.-owned research-based pharmaceutical companiesC&EN January 17, 2000, Food & Drug Administration,Pharmaceutical Research & Manufacturers of America: PhRMA Annual Survey 2000. Ari Koskinen Laboratory of Organic ChemistryNew Drug Development Ari KoskinenLaboratory of Organic ChemistryR&D By Geographic Area; 2001AfricaAmericasEuropeAsia-PacificAustraliaMiddle EastOthers Ari KoskinenLaboratory of Organic Chemistryab$ 1.7 bn (2003) per product is spent onR&D StageSynthesis/extractionBiological screening/pharmacological testingToxicology/safetyDosage formulationClinical evaluationProcess development formanufacturing/ qualitycontrolRegulatoryOther% of spendinga 11.0 16.0 6.0 9.6 34.5 9.6 3.8 9.4% of employeesb 12.9 18.3 7.8 11.6 24.3 10.3 4.8 10.0 Company financed R&D in US based on 1995 figures totalling $ 11.8 bn US scientific and professional personnel totaling 34, 784 employees Source: Pharmaceutical Research & Manufacturers of America, Industry Profile 19972003 data: C&EN 2003, 81 (50), 8. Ari Koskinen Laboratory of Organic ChemistryMarket Exclusivity Times Decrease Ari KoskinenLaboratory of Organic ChemistryDevelopment pipeline Ari KoskinenLaboratory of Organic ChemistryTop 10 Therapies December 6, 2004Volume 82, Number 49pp. 18-29 Ari KoskinenLaboratory of Organic ChemistryTop 10 Products December 6, 2004Volume 82, Number 49pp. 18-29 Ari KoskinenLaboratory of Organic ChemistryMergers December 6, 2004Volume 82, Number 49pp. 18-29 Ari KoskinenLaboratory of Organic ChemistryOff Patent December 6, 2004Volume 82, Number 49pp. 18-29 Ari KoskinenLaboratory of Organic ChemistryPatents expiring December 6, 2004Volume 82, Number 49pp. 18-29 Ari KoskinenLaboratory of Organic ChemistryPromising New Drugs December 6, 2004Volume 82, Number 49pp. 18-29 Ari KoskinenLaboratory of Organic ChemistryDiversity of Drug StructuresBODFEHOO GNatural Products as Drug Leads O MeMeOONH ClHOOMeO MeA1 Me OCl O AO Me O HONO2Me O OC O Me MeO O OMe OHMe OMe O O OOH OH OHO G OOMe OO HO OO OO HOMeA2OH Me MeMeOHOO OHOHO OMeMeOMeEverninomicin 13,384-1Me Callipeltoside AClinhibits proliferation of KB and P388 cells protects cells infected with HIVO16OHMeBr46OMe 43OHOMe 33O OHN 29OO24 OO 1N O 9O 5HOOHAO O MeB O H Me C D H OH E O。省略部分。 10% Na2CO3, Fmoc-ClNFmoc 10 acetoneOH 59% 96%NFmocCOOH 11Nevalainen, M. J. Org. Chem. 2001, 66, 2061-2066.Ari KoskinenLaboratory of Organic ChemistryProlines in Turns[Arg-Val-Asp-Val]3Ala Leu Gly AlaAla Pro Gly Ala cAla MP Gly Ala tAla MP Gly Ala MP = N[Val-Asp-Val-Arg]3O Krische, M.J. Ari Koskinen Laboratory of Organic ChemistrySynthesis of TetrapeptidesAlaXGlyAlaCbzOHH2NOtBuCbzOHH2NOMeCbzCbzOtBuOHCbzH2NOMeOMeX = Leu, Pro, 4-MeProCbzCbzOMeNHMe Krische, M.J. Ari KoskinenLaboratory of Organic Chemistry----Proline Conformations Figure 4dx4HOCHNx1CC x2x3 C H HOCHNCCC HRamachandran ARamachandran Bx1: 0 - -30°x2: +15 - +50°x3: -15 - -30°x4: +5 - +25°x1:x2:x3:x4:+20 -30+20 -5+35°-40°+35°-20° Krische, M.J.; O’Connell, J. Ari KoskinenLaboratory of Organic Chemistryγ^^^^^^^^^^NMR of 4-Alkyl Proline TetrapeptidesFigure 4b: Trans 4-Methyl Proline Peptide - Proline Spin System Analysis DMSOFigure 4c: Cis 4-Methyl Proline Peptide - Proline Spin System Analysis DMSOO(δ1.95) β1 6.3(4.2)(δ2.41) γ6.99.5(δ3.71) δ1O(δ7.23) β1Me(δ3.01) δ1(8.2)3.1-12.59.56.6(3.6)-10.3(4.1)6.63.19.9-9.9 α(δ4.53)8.7 β2(δ1.62) Me(δ0.97) δ2(δ3.14) α(δ4.23)9.3 β2(δ2.23)7.0 δ2(δ3.95)x1 αβ:x2 βγ:x3 γ δ: JC = 8.7?Jt = 5.1 JC = 6.3?Jt = -5.3 JC = 6.9?Jt = 5.9x = 21°x = +13°x = 37°x = -13°x = 34°x = +14°Markedly Non-PlanarStrongly Prefers B Form(i.e. Equatorial 4-Methylx1 αβ:x3 γ δ: JC = 9.3 ?Jt = -2.5 JC = 7.0?Jt = -6.8x = 15°x = -6°x = 33°x = -17°Non-PlanarStrongly Prefers A FormCDCl3CDCl3Oβ1 6.0(4.8)γ6.79.0δ1Oβ1Meδ1α(8.3)9.12.6 -12.7β29.2 6.6Me(4.3)δ2-9.3(3.5)α9.57.0β2(2.3)γ7.89.9δ2-9.9αβ:JC = 9.1x = 17°βγ:γ δ:?Jt = 5.7 JC = 6.0?Jt = -5.3 JC = 6.7x = +14°x = 39°x = -13°x = 35°Markedly Non-PlanarStrongly Prefers B Formx1 αβ:x3 γ δ:JC = 9.5?Jt = -3.5JC = 7.8x = 13°x = -9°x = 28°Non-PlanarStrongly Prefers A Form?Jt = 4.7x = +11°?Jt = -6.8x = -17° Krische, M.J.; O’Connell, J. Ari KoskinenLaboratory of Organic Chemistry1RNHONHONH-OCNOXRNABCHO2COHO2CHO2CNHHO2C N NOOCO2H2HO2CNHHO2C N NOOCO2H3 4 Ari KoskinenLaboratory of Organic ChemistryVectorial Recognition and Cleavage of ProteinsAA'CDE_B'BNFguanidineG +HNNHNNH2HONHHNlinker of a adjustablelenght and conformationNHfluorescence quencerON NNmetal chelateMBP-avidin fusion protein MBP Avidin12345 Ari KoskinenLaboratory of Organic Chemistry Ari KoskinenLaboratory of Organic ChemistryConclusionssmall conformationally constrained amino acidsurrogates can be constructedTheir incorporation to β-turns can be achievedA designed signal orthogonal to native ones(peptide/DNA?/RNA?) can be used to directchemical cleavage Ari KoskinenLaboratory of Organic Chemistry Ari KoskinenLaboratory of Organic Chemistry
關 鍵 詞:
優秀 學術報告 ppt ari koskinen 示例
 天天文庫所有資源均是用戶自行上傳分享,僅供網友學習交流,未經上傳用戶書面授權,請勿作他用。
關于本文
本文標題:優秀學術報告PPT示例(Ari-Koskinen).ppt
鏈接地址: http://www.094347.live/p-55627590.html
關于我們 - 網站聲明 - 網站地圖 - 資源地圖 - 友情鏈接 - 網站客服點擊這里,給天天文庫發消息,QQ:1290478887 - 聯系我們

本站為“文檔C2C交易模式”,即用戶上傳的文檔直接賣給(下載)用戶,本站只是中間服務平臺,本站所有文檔下載所得的收益歸上傳人(含作者)所有【成交的100%(原創)】。本站是網絡服務平臺方,若您的權利被侵害,侵權客服QQ:1290478887 歡迎舉報。

[email protected] 2017-2027 http://www.094347.live 網站版權所有

粵ICP備19057495號 

收起
展開
有没有苹果软件赚钱的 福建11选5开奖时 海南环岛彩票 东京快乐8开奖 炒股秘籍 今天甘肃快三遗漏推荐号码 甘肃快三今天的开奖号 福建11选五开奖结果手机 股票融资咨询 大发快三彩票下载 买一千块股票亏了两千